BioArctic is engaged in the development of new diagnostics that improve the ability to diagnose and monitor the treatment of Alzheimer’s and Parkinson’s disease. The company conducts a number of projects in collaboration with commercial and academic partners.
Among other things, BioArctic is developing biochemical methods based on the company’s antibodies to be applied to cerebral spinal fluid (CSF) testing. Beyond this, the company is exploring the possibilities to measure biomarkers with a simple blood test. BioArctic is also active in a project to improve the diagnostic imaging (PET) of the brain of Alzheimer’s patients. The goal is to create tools to better diagnose the disease, follow the disease progression and objectively measure the effect of drug treatment.
Alzheimer’s disease diagnostics is owned by BioArctic and Parkinson’s disease diagnostics is in collaboration with AbbVie.